Compugen Ltd (NASDAQ:CGEN)

3.32
Delayed Data
As of Nov 16
 -0.09 / -2.64%
Today’s Change
2.25
Today|||52-Week Range
5.00
+32.80%
Year-to-Date
Bristol-Myers, Infinity to Test Opdivo Combo for Bladder Cancer
Nov 07 / Zacks.com - Paid Partner Content
What's in the Cards for Perrigo (PRGO) This Earnings Season?
Nov 06 / Zacks.com - Paid Partner Content
Compugen (CGEN) Reports Q3 Loss
Nov 07 / Zacks.com - Paid Partner Content
What Lies in Store for Ligand (LGND) This Earnings Season?
Nov 06 / Zacks.com - Paid Partner Content

Today’s Trading

Previous close3.41
Today’s open3.35
Day’s range3.26 - 3.40
Volume51,964
Average volume (3 months)194,826
Market cap$197.9M
Data as of 3:59pm ET, 11/16/2018

Growth & Valuation

Earnings growth (last year)-16.13%
Earnings growth (this year)+39.81%
Earnings growth (next 5 years)--
Revenue growth (last year)-100.00%
P/E ratioNM
Price/Sales--
Price/Book5.81

Competitors

 Today’s
change
Today’s
% change
NKNantKwest Inc-0.03-1.30%
NTGNNeon Therapeutics In...-0.09-1.28%
SYBXSynlogic Inc+0.89+10.27%
BLCMBellicum Pharmaceuti...-0.20-4.45%
Data as of 4:00pm ET, 11/16/2018

Financials

Next reporting dateFebruary 12, 2019
EPS forecast (this quarter)-$0.19
Annual revenue (last year)$0.00
Annual profit (last year)-$37.1M
Net profit margin--

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Anat Cohen-Dayag
Chief Operating &
Financial Officer
Ari Krashin
Corporate headquarters
Holon, Tel Aviv

Forecasts